AU
UK
CA
US
IND
NZ
Last update at 2026-06-09T15:52:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
MESA LABS DECLARES QUARTERLY DIVIDEND
Mon 07 Apr 25, 07:00 PMMesa Labs Announces Third Quarter Results
Tue 04 Feb 25, 01:00 PM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -0.38900M | 3.57M | 2.30M | 3.43M | 8.62M |
| Minority interest | - | - | - | - | - |
| Net income | 0.93M | 1.87M | 3.27M | 1.35M | 7.48M |
| Selling general administrative | 72.44M | 60.31M | 45.70M | 37.83M | 31.30M |
| Selling and marketing expenses | 37.44M | 28.31M | 18.48M | 12.91M | 8.26M |
| Gross profit | 133.69M | 109.09M | 87.01M | 64.93M | 60.92M |
| Reconciled depreciation | 33.82M | 25.07M | 17.66M | 12.99M | 9.43M |
| Ebit | -30.50400M | -20.36600M | -5.30200M | -4.90000M | 25.93M |
| Ebitda | 3.32M | 4.70M | 12.36M | 8.09M | 35.36M |
| Depreciation and amortization | 33.82M | 25.07M | 17.66M | 12.99M | 9.43M |
| Non operating income net other | 1.06M | - | -2.03100M | 1.44M | -1.15800M |
| Operating income | -30.50400M | -20.36600M | -5.30200M | -4.90000M | 9.78M |
| Other operating expenses | 215.76M | 179.63M | 121.58M | 109.89M | 85.28M |
| Interest expense | 3.71M | 3.88M | 8.02M | 5.50M | 0.00000M |
| Tax provision | -1.31900M | 1.70M | -0.97100M | 2.08M | 1.14M |
| Interest income | - | - | 0.11M | 0.96M | - |
| Net interest income | -4.77000M | -3.88500M | -7.91700M | -4.54400M | - |
| Extraordinary items | - | - | - | - | -0.04300M |
| Non recurring | - | - | 0.09M | 0.35M | 8.07M |
| Other items | - | - | - | - | - |
| Income tax expense | -1.31900M | 1.70M | -0.97100M | 2.08M | 1.14M |
| Total revenue | 219.08M | 184.34M | 133.94M | 117.69M | 103.14M |
| Total operating expenses | 130.37M | 104.39M | 74.66M | 57.14M | 43.06M |
| Cost of revenue | 85.39M | 75.25M | 46.92M | 52.75M | 42.22M |
| Total other income expense net | 30.11M | 23.94M | 7.61M | 8.33M | -9.23200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 0.93M | 1.87M | 3.27M | 1.35M | 7.48M |
| Net income applicable to common shares | 0.93M | 1.87M | 3.27M | 1.35M | 7.48M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 661.83M | 707.37M | 600.15M | 420.21M | 156.77M |
| Intangible assets | 18.23M | 250.12M | 111.74M | 119.87M | 33.22M |
| Earning assets | - | - | - | - | - |
| Other current assets | 86.06M | 74.97M | 39.14M | 41.41M | 1.60M |
| Total liab | 268.35M | 313.57M | 193.92M | 200.19M | 45.46M |
| Total stockholder equity | 393.48M | 393.80M | 406.23M | 220.01M | 111.31M |
| Deferred long term liab | 34.03M | - | 16.27M | 32.55M | - |
| Other current liab | 19.95M | 22.81M | 18.31M | 14.69M | 14.67M |
| Common stock | 332.08M | 313.46M | 317.65M | 158.02M | 39.82M |
| Capital stock | 332.08M | 313.46M | 317.65M | 158.02M | 39.82M |
| Retained earnings | 74.20M | 76.67M | 72.46M | 71.93M | 73.30M |
| Other liab | 35.97M | 39.71M | 193.92M | 32.65M | 1.18M |
| Good will | 286.44M | 291.17M | 160.84M | 141.54M | 66.38M |
| Other assets | 2.76M | 554.43M | 275.14M | 11.46M | 1.32M |
| Cash | 32.91M | 49.35M | 263.87M | 81.38M | 10.19M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 43.36M | 48.05M | 32.58M | 26.01M | 23.66M |
| Current deferred revenue | 14.41M | 14.58M | 8.78M | 6.81M | 3.96M |
| Net debt | 137.36M | 171.79M | -117.16700M | 59.99M | 12.55M |
| Short term debt | 2.87M | 2.77M | 1.02M | 1.09M | 2.12M |
| Short long term debt | - | - | - | - | 2.12M |
| Short long term debt total | 170.27M | 221.13M | 146.70M | 141.37M | 22.74M |
| Other stockholder equity | -12.79500M | 323.13M | 16.12M | 0.06M | 0.18M |
| Property plant equipment | 28.15M | 28.62M | 22.00M | 22.07M | 22.23M |
| Total current assets | 118.97M | 124.32M | 303.01M | 122.79M | 33.62M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 107.04M | 393.80M | 294.49M | -41.39400M | 44.93M |
| Short term investments | - | - | - | - | - |
| Net receivables | 42.55M | 41.22M | 23.79M | 21.13M | 12.52M |
| Long term debt | 183.27M | 218.37M | 145.68M | 140.28M | 20.61M |
| Inventory | 34.64M | 24.61M | 11.18M | 14.23M | 6.77M |
| Accounts payable | 6.13M | 7.90M | 4.47M | 3.41M | 2.90M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12.79500M | 3.67M | 16.12M | -9.94000M | -1.81500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 332.08M | - | 317.65M | 158.02M | 39.82M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 74.20M | - | 72.46M | 71.93M | 73.30M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 208.96M | 11.83M | 275.14M | 275.35M | 0.25M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 542.86M | 583.05M | 297.14M | 297.41M | 123.14M |
| Capital lease obligations | 2.87M | 2.77M | 1.02M | 1.09M | - |
| Long term debt total | 183.27M | - | 145.68M | 140.28M | 20.61M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -9.49400M | -305.22500M | -1.99200M | -185.58500M | -3.88000M |
| Change to liabilities | -4.90500M | 3.96M | 0.65M | -2.20800M | 6.57M |
| Total cashflows from investing activities | -9.49400M | -305.22500M | -1.99200M | -185.58500M | -3.88000M |
| Net borrowings | -36.00000M | 49.00M | -0.66400M | 144.07M | -23.62500M |
| Total cash from financing activities | -33.32800M | 52.58M | 146.23M | 231.28M | -21.67200M |
| Change to operating activities | -3.87000M | -3.35100M | 2.56M | -2.57900M | 2.58M |
| Net income | 0.93M | 1.87M | 3.27M | 1.35M | 7.48M |
| Change in cash | -16.43600M | -214.51900M | 182.49M | 71.19M | 4.72M |
| Begin period cash flow | 49.35M | 263.87M | 81.38M | 10.19M | 5.47M |
| End period cash flow | 32.91M | 49.35M | 263.87M | 81.38M | 10.19M |
| Total cash from operating activities | 27.98M | 39.22M | 37.07M | 26.56M | 30.55M |
| Issuance of capital stock | 0.00000M | 0.00000M | 145.94M | 85.00M | - |
| Depreciation | 33.82M | 25.07M | 17.66M | 12.99M | 9.43M |
| Other cashflows from investing activities | -4.95000M | - | - | -184.08700M | -2.61800M |
| Dividends paid | 3.41M | 3.34M | 3.17M | 2.72M | 2.46M |
| Change to inventory | -10.18200M | -1.04500M | 0.93M | 0.41M | 2.57M |
| Change to account receivables | -2.12100M | -6.75200M | -0.64700M | -1.66500M | 1.59M |
| Sale purchase of stock | 7.00M | -0.87500M | 150.36M | 177.44M | -5.09500M |
| Other cashflows from financing activities | 6.08M | 76.92M | 3.46M | -5.44100M | 6.42M |
| Change to netincome | 10.34M | 19.48M | 11.32M | 6.92M | 5.78M |
| Capital expenditures | 4.54M | 4.43M | 1.99M | 1.50M | 1.26M |
| Change receivables | -2.12100M | - | -0.64700M | -1.66500M | 1.59M |
| Cash flows other operating | 1.03M | - | 7.16M | 10.11M | 4.61M |
| Exchange rate changes | - | - | - | -1.05600M | -0.28600M |
| Cash and cash equivalents changes | -14.83900M | - | 181.31M | 71.19M | 4.72M |
| Change in working capital | -17.11200M | -7.19200M | 5.25M | -3.13700M | 7.89M |
| Stock based compensation | 12.54M | 11.39M | 9.27M | 5.53M | 4.21M |
| Other non cash items | 1.30M | 7.96M | 5.12M | 11.80M | 4.01M |
| Free cash flow | 23.44M | 34.79M | 35.08M | 25.06M | 29.29M |
Sector: Technology Industry: Scientific & Technical Instruments
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MLAB Mesa Laboratories Inc |
-0.21 0.19% | 108.25 | 672.06 | 35.21 | 2.66 | 1.41 | 3.64 | 19.89 |
| KYCCF Keyence |
-5.03 1.05% | 472.00 | 41.66 | 38.76 | 0.11 | 5.69 | 0.10 | 0.19 |
| COHR Coherent Inc |
-33.07 8.23% | 368.86 | 333.78 | 46.73 | 10.24 | 7.63 | 10.78 | 62.92 |
| GRMN Garmin Ltd |
0.27 0.11% | 235.50 | 30.87 | 28.41 | 7.05 | 5.74 | 6.75 | 23.69 |
| HXGBY Hexagon AB ADR |
0.16 1.54% | 10.55 | 33.46 | 33.33 | 6.00 | 2.83 | 6.50 | 29.28 |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982
12100 West Sixth Avenue, Lakewood, CO, United States, 80228
| Name | Title | Year Born |
|---|---|---|
| Mr. Gary M. Owens | CEO, Pres & Director | 1968 |
| Mr. John V. Sakys | VP, CFO & Chief Accounting Officer | 1969 |
| Mr. Brian David Archbold | Sr. VP of Continuous Improvement | 1976 |
| Mr. Bryan T. Leo | Sr. VP of Operations | NA |
| Mr. Garrett Krushefski | Sr. VP of Operations | NA |
| Mr. Peter M. Dansky | Pres of Clinical Genomics | 1961 |
| Mr. Gary M. Owens | CEO, President & Director | 1968 |
| Mr. Brian David Archbold | Senior Vice President of Continuous Improvement | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...